Psychoactive Bath Salts and Neurotoxicity Risk.
Psychoactive
bath salts
hallucinogen
neurotoxicity
synthetic cathinones
Journal
Turkish journal of pharmaceutical sciences
ISSN: 2148-6247
Titre abrégé: Turk J Pharm Sci
Pays: Turkey
ID NLM: 101717890
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
05
11
2018
accepted:
06
12
2018
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
ppublish
Résumé
Synthetic cathinones are new designer drugs that possess hallucinogenic and psychostimulant properties, and are designed to mimic the effects of illegal substances such as cocaine, amphetamines, and 3.4-methylenedioxymethamphetamine (ecstasy) and to produce rewarding effects, circumventing existing laws and penalties. Synthetic cathinones, also referred to as 'bath salts', have become popular particularly among young people since the mid-2000s. Similar to other psychomotor stimulants, synthetic cathinones have the potential to increase monoamine concentration in the synaptic cleft by targeting the plasma membrane transporters of dopamine, norepinephrine, and serotonin. Because of their structural similarities to amphetamines, it has been suggested that synthetic cathinones may have a neurotoxicity profile similar to that of their amphetamine congeners. Therefore, it has been hypothesized that synthetic cathinones may induce neurotoxicity on monoamine nerve endings in the striatum, hippocampus, and cortex. To date, with regard to synthetic cathinone neurotoxicity, parameters such as monoamine depletion, biosynthetic enzyme inhibition, cytotoxicity, generation of reactive oxygen species, pro-oxidation status, and the ability to induce neuroinflammation were investigated in both
Identifiants
pubmed: 32454785
doi: 10.4274/tjps.galenos.2018.40820
pii: 21097
pmc: PMC7227911
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
235-241Informations de copyright
©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Toxicol Lett. 2012 Jun 1;211(2):144-9
pubmed: 22459606
J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
pubmed: 15163680
Pharmacol Biochem Behav. 2013 Jan;103(3):501-9
pubmed: 23099177
J Addict Med. 2018 Jul/Aug;12(4):336-338
pubmed: 29533309
Neuropharmacology. 2014 Dec;87:206-13
pubmed: 24594476
Neurotox Res. 2017 Nov;32(4):594-602
pubmed: 28646469
J Neurochem. 2012 Mar;120(6):1097-107
pubmed: 22191803
Int J Cardiol. 2014 Mar 1;172(1):263-5
pubmed: 24491861
Psychopharmacology (Berl). 2014 Aug;231(16):3119-29
pubmed: 24705904
Toxicol Lett. 2011 Mar 25;201(3):191-5
pubmed: 21187132
J Pharmacol Exp Ther. 2011 Nov;339(2):530-6
pubmed: 21810934
J Chromatogr A. 2014 Dec 29;1374:93-101
pubmed: 25482853
Toxicol Appl Pharmacol. 2015 Jul 1;286(1):27-35
pubmed: 25817894
Curr Top Behav Neurosci. 2017;32:209-230
pubmed: 27753008
Eur J Pharmacol. 1999 Sep 17;381(1):63-9
pubmed: 10528135
J Emerg Med. 2014 May;46(5):632-42
pubmed: 24565885
Eur J Pharmacol. 2013 Jan 5;698(1-3):1-5
pubmed: 23178799
Forensic Sci Int. 2013 Sep 10;231(1-3):42-53
pubmed: 23890615
J Neurochem. 2013 Apr;125(1):102-10
pubmed: 23205838
Ann Forensic Res Anal. 2017;4(2):
pubmed: 30288398
J Med Toxicol. 2012 Mar;8(1):33-42
pubmed: 22108839
Case Rep Psychiatry. 2016;2016:3460849
pubmed: 27418996
Annu Rev Pharmacol Toxicol. 2007;47:681-98
pubmed: 17209801
Neurosci Lett. 2016 Aug 26;629:125-130
pubmed: 27320055
Front Psychiatry. 2017 Aug 23;8:156
pubmed: 28878698
Psychopharmacology (Berl). 2017 Jan;234(1):117-127
pubmed: 27709249
Life Sci. 2014 Feb 27;97(1):2-8
pubmed: 23911668
P T. 2012 Oct;37(10):571-95
pubmed: 23115465
Clin Pharmacol. 2013 Jul 02;5:109-15
pubmed: 23869180
Drug Metab Rev. 2018 May;50(2):125-139
pubmed: 29540067
PLoS One. 2014 Jun 03;9(6):e99002
pubmed: 24892744
Toxicol Lett. 2014 Sep 2;229(2):349-56
pubmed: 24973490
J Neurochem. 2015 Apr;133(2):211-22
pubmed: 25626880
Drug Test Anal. 2011 Jul-Aug;3(7-8):439-53
pubmed: 21755607
ACS Chem Neurosci. 2017 Apr 19;8(4):850-859
pubmed: 28067045
Mil Med. 2012 Sep;177(9):1041-8
pubmed: 23025133
J Psychopharmacol. 2014 Nov;28(11):1053-63
pubmed: 25237120
Pharmacol Rep. 2018 Dec;70(6):1097-1104
pubmed: 30308460
Toxicol Appl Pharmacol. 2016 Feb 15;293:10-20
pubmed: 26747301
Neurotoxicol Teratol. 2018 May - Jun;67:10-17
pubmed: 29501570